| Code | CSB-RA011613MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Vilamakitug, targeting interleukin-1 alpha (IL1A), a pro-inflammatory cytokine of the IL-1 family. IL1A plays a critical role in initiating and amplifying inflammatory responses by binding to the IL-1 receptor and activating downstream signaling pathways involved in immune cell activation and cytokine production. This cytokine is implicated in various inflammatory and autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and certain autoinflammatory syndromes. Additionally, IL1A has been associated with cancer-related inflammation, where it contributes to tumor microenvironment modulation and disease progression.
Vilamakitug is a therapeutic monoclonal antibody developed to neutralize IL1A activity, currently under investigation for treating inflammatory conditions and cancer. This biosimilar antibody provides researchers with a valuable tool for studying IL1A-mediated inflammatory pathways, investigating disease mechanisms, and exploring potential therapeutic interventions. It enables experimental work in immunology, oncology, and inflammation research, supporting the development of novel treatment strategies targeting IL-1 signaling.
There are currently no reviews for this product.